Van Strum & Towne Inc. decreased its holdings in Pfizer Inc. (NYSE:PFE) by 6.8% in the third quarter, HoldingsChannel reports. The firm owned 58,711 shares of the biopharmaceutical company’s stock after selling 4,300 shares during the quarter. Pfizer accounts for about 1.4% of Van Strum & Towne Inc.’s portfolio, making the stock its 28th biggest position. Van Strum & Towne Inc.’s holdings in Pfizer were worth $2,096,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in the company. Shine Investment Advisory Services Inc. purchased a new position in Pfizer during the second quarter valued at $102,000. Mckinley Capital Management LLC Delaware purchased a new position in Pfizer during the second quarter valued at $103,000. D. Scott Neal Inc. lifted its position in Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares in the last quarter. Herndon Capital Management LLC purchased a new position in Pfizer during the second quarter valued at $120,000. Finally, Lipe & Dalton lifted its position in Pfizer by 6.9% during the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after purchasing an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 69.87% of the company’s stock.
Several equities analysts recently weighed in on the company. Sanford C. Bernstein set a $43.00 target price on Pfizer and gave the company a “buy” rating in a research report on Tuesday, January 30th. Goldman Sachs Group set a $36.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Tuesday, January 30th. UBS Group set a $42.00 target price on Pfizer and gave the company a “buy” rating in a research report on Wednesday, January 31st. BMO Capital Markets set a $39.00 target price on Pfizer and gave the company a “buy” rating in a research report on Tuesday, October 31st. Finally, Berenberg Bank set a $36.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company’s stock. Pfizer currently has an average rating of “Hold” and an average price target of $39.45.
Shares of Pfizer Inc. (PFE) opened at $34.98 on Thursday. Pfizer Inc. has a twelve month low of $31.67 and a twelve month high of $39.43. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. The stock has a market capitalization of $208,510.00, a PE ratio of 9.94, a PEG ratio of 2.08 and a beta of 0.94.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The firm had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. During the same period in the previous year, the firm posted $0.47 earnings per share. The business’s revenue was up .6% compared to the same quarter last year. research analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be paid a dividend of $0.34 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a yield of 3.89%. The ex-dividend date is Thursday, February 1st. Pfizer’s payout ratio is presently 38.64%.
Pfizer declared that its board has approved a share repurchase plan on Monday, December 18th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its stock is undervalued.
TRADEMARK VIOLATION NOTICE: “Pfizer Inc. (PFE) Shares Sold by Van Strum & Towne Inc.” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://sportsperspectives.com/2018/02/08/pfizer-inc-pfe-shares-sold-by-van-strum-towne-inc.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.